List view / Grid view
In the wake of the UK’s agreed deal with the EU, Andrew Howard, Deputy Director for Trade, Regulation and Analysis in the Office for Life Sciences, offers advice to those life sciences businesses navigating the transition to a new regulatory landscape.
A new report shows that the UK is trailing behind the rest of Europe in the diagnosis and treatment of cancer.
7 July 2016 | By Victoria White, Digital Content Producer
In the recent Referendum, the majority voted against the UK's continued membership of the EU. Now, the EMA has issued a statement on the outcome of the vote...
30 June 2016 | By Victoria White, Digital Content Producer
In the statement, EFPIA underscores the importance of ensuring that the patient is at the centre of all subsequent decisions...
27 June 2016 | By Victoria White, Digital Content Producer
While a Brexit undoubtedly creates significant issues for the UK pharma industry, opportunities remain for the sector to thrive, according to GlobalData...
20 June 2016 | By Caroline Richards, Editor, European Pharmaceutical Review
With only days to go until Britain holds a referendum on its EU membership, we can't help but wonder how you feel...
8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO
In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...
16 March 2016 | By Steve Bates, BioIndustry Association (BIA) Chief Executive
Here, Steve Bates, Chief Executive of the BioIndustry Association (BIA), makes a case for the UK remaining in the EU from the perspective of the life sciences sector...
13 May 2015 | By Victoria White
Businesses, including those in the pharmaceutical sector, should start assessing the potential consequences of a Brexit, advises Hogan Lovells...
